Transcutaneous Dysport Injection for Treatment of Upper Eyelid Retraction Associated with Thyroid Eye Disease

Salour, Hossein; Bagheri, Babak; Aletaha, Maryam; Babsharif, Babak; Kleshadi, Mandana; Abrishami, M; Bagheri, Abbas

doi:10.3109/01676830903324268

Cited by 29 publications

(29 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The effect of BTX-A remained for (19.00 ± 1.71 weeks) by a single session. This matches with Ozkat and colleagues, 12 Shih and colleagues, 14 Costa and colleagues, 15 and Salour and colleagues 6 but does not match with Uddin and Davies 9 as their patients received multiple injections.…”

Section: Discussionsupporting

confidence: 66%

“…With regard to the BTX-A group, our result matches with several studies. 4,6,9,12 – 15 We had complications in the form of ptosis and ecchymosis which have been reported in some studies. Other complications as diplopia and ocular mobility affection have been reported by Uddin and Davies.…”

Section: Discussionmentioning

confidence: 75%

“…Correction of upper eyelid retraction is important to improve the quality of life of TED patients. 5,6…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Comparison between hyaluronic acid filler and botulinum toxin type A in the treatment of thyroid upper eyelid retraction

Hussien¹,

Hassan

El-Haddad

2020

Ophthalmol Eye Dis

View full text Add to dashboard Cite

Purpose: The aim of this study was to compare between hyaluronic acid filler (HA) and botulinum toxin type A (BTX-A) in the treatment of thyroid upper eyelid retraction. Study design: This was a prospective comparative study. Methods: A total of 50 eyes with upper thyroid eyelid retraction were divided into 2 groups. Each group included 25 eyes, (a) hyaluronic acid filler (HA) group: received subconjunctival HA injection and (b) botulinum toxin (BTX-A) group: received subconjunctival botulinum toxin type A injection. Full ophthalmic examination and thyroid profile were done. Marginal reflex distance 1 (MRD1) and total palpebral fissure height (TPFH) were measured before and after injection weekly for 6 months. Results: There is no significant difference between the two groups regarding MRD1 till the 10th week of follow up, then it became significant from the 11th to 15th week with better results in HA filler group, then the difference between the two groups become highly significant from the 16th week afterward with better results for the HA filler over the BTX-A. With regard to TPFH, there were significant differences between the BTX-A group and the HA group with a better result in BTX-A group in the first 8 weeks. Then the difference became insignificant till the 18th week. Then the difference became significant from the 19th till the 24th week with a better result in HA group. Conclusion: HA filler has better result in treating thyroid upper eyelid retraction than BTX-A due to its predictable controllable effect, also, due to the longer duration of action and fewer side effects.

show abstract

Section: Discussionsupporting

confidence: 66%

Section: Discussionmentioning

confidence: 75%

See 1 more Smart Citation

Comparison between hyaluronic acid filler and botulinum toxin type A in the treatment of thyroid upper eyelid retraction

Hussien¹,

Hassan

El-Haddad

2020

Ophthalmol Eye Dis

View full text Add to dashboard Cite

show abstract

“…When injected via a transcutaneous approach, Btx-A can achieve similar lid lowering effects with good safety and efficacy 34,35,37,39 . In addition, the study by Costa et al found the lid lowering effects of Btx-A lasted longer in patients with fibrotic-stage TED as compared to patients with congestive-stage TED 40 .…”

Section: Induce Ptosis/reduce Lid Retractionmentioning

confidence: 99%

Uses of Botulinum Toxin a in Ophthalmology

Teo

Chee

2012

Proceedings of Singapore Healthcare

View full text Add to dashboard Cite

show abstract

“…Temporary improvement of the palpebral fissure height has been observed with doses of 2.5-10 U Botox delivered by transconjunctival injection just above the upper tarsal border into the levator-Müller muscle complex. 87,88,89 Salour et al 90 reported that a single dose of 20 U of Dysport injected transcutaneously at the central superior tarsal border into the levator aponeurosis and Müller muscle was a safe and effective treatment. Ptosis and diplopia may arise as minor complications.…”

Section: Introductionmentioning

confidence: 99%

Use of Botulinum Neurotoxin in Ophthalmology

Başar

Arıcı

2016

tjo

View full text Add to dashboard Cite

Botulinum neurotoxin (BoNT) is the first biological toxin used in the treatment of ophthalmic diseases and to decrease skin wrinkles as an aesthetic agent. When used appropriately, it weakens the force of muscular contraction and/or inhibits glandular secretion. The most common areas for botulinum toxin treatment are the upper face, including the glabella, forehead, brows, and lateral canthal lines, or crow’s feet. By relaxing the muscles causing wrinkles, non-permanent results may be achieved with its use. BoNT has gained widespread use in a variety of ophthalmic diseases. The effect of BoNT is temporary, but the therapeutic benefit is usually maintained even after repeated injections. Treatment is usually well tolerated. Complications and side effects associated with the treatment are rare and temporary. Complications occur due to weakness (chemodenervation) of adjacent muscle groups, immunological mechanisms and injection technique. Current therapeutic indications, doses, complications and contraindications of BoNT use in the following disorders related to ophthalmology were investigated: aesthetic use, strabismus, blepharospasm, hemifacial spasm, eyelid retraction, entropion, lacrimal hypersecretion syndrome, and facial paralysis.

show abstract

Transcutaneous Dysport Injection for Treatment of Upper Eyelid Retraction Associated with Thyroid Eye Disease

Cited by 29 publications

References 17 publications

Comparison between hyaluronic acid filler and botulinum toxin type A in the treatment of thyroid upper eyelid retraction

Comparison between hyaluronic acid filler and botulinum toxin type A in the treatment of thyroid upper eyelid retraction

Uses of Botulinum Toxin a in Ophthalmology

Use of Botulinum Neurotoxin in Ophthalmology

Contact Info

Product

Resources

About